Harrow, Inc.

Harrow, Inc. is an eyecare pharmaceutical company focused on the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. Its business is organized into two segments: Branded and ImprimisRx. The Branded segment includes a portfolio of proprietary and generic ophthalmic products such as IHEEZO (a chloroprocaine hydrochloride ophthalmic gel), IOPIDINE, VEVYE, ZERVIATE, BYQLOVI, MAXITROL, ILEVRO, NEVANAC, BYOOVIZ (a biosimilar to LUCENTIS for wet AMD, RVO, and mCNV), VIGAMOX (an antibiotic for bacterial conjunctivitis), OPUVIZ (a biosimilar to EYLEA for wet AMD, RVO, DME, and DR), MAXIDEX, FLAREX, TRIESENCE, and NATACYN. The ImprimisRx segment provides ophthalmology-focused compounded medications. The company serves the U.S. market.

Harrow, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol HROW. The company's financials are reported in U.S. Dollars (USD), as it is based in the United States and primarily operates within the U.S. healthcare market.

Harrow, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This means the company is involved in the development and production of pharmaceutical products, with a focus on specialty and generic drugs, particularly for ophthalmic (eye-related) conditions. As a specialty generic drug manufacturer, Harrow produces both branded and compounded medications for eye care.

Harrow, Inc. organizes its business into two segments: Branded and ImprimisRx. The Branded segment offers a wide range of ophthalmic products, including IHEEZO (a gel for ophthalmic use), IOPIDINE, VEVYE, ZERVIATE, BYQLOVI, MAXITROL (eye drops), ILEVRO and NEVANAC (NSAID eye drops for cataract surgery pain), BYOOVIZ (a biosimilar for wet AMD, RVO, and mCNV), VIGAMOX (antibiotic for bacterial conjunctivitis), OPUVIZ (a biosimilar for wet AMD, RVO, DME, and DR), MAXIDEX and FLAREX (steroid eye drops for inflammatory conditions), TRIESENCE (steroid injection for ophthalmic diseases and vitrectomy visualization), and NATACYN (antifungal for fungal eye infections). The ImprimisRx segment focuses on compounded medications tailored for ophthalmology.

Harrow, Inc. is headquartered in the United States and serves the U.S. market exclusively, as indicated by its country and region being the United States (us). The company's operations are focused on the discovery, development, and commercialization of ophthalmic pharmaceutical products for the American healthcare system. Its products are distributed across the U.S. to treat various eye conditions, including infections, inflammation, dry eye, and retinal diseases.